Woolf T F, Pool W F, Bjorge S M, Chang T, Goel O P, Purchase C F, Schroeder M C, Kunze K L, Trager W F
Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research Division Warner-Lambert Co., Ann Arbor, MI 48106.
Drug Metab Dispos. 1993 Sep-Oct;21(5):874-82.
Tacrine's [1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate, (THA)] metabolic fate was examined using human and rat liver microsomal preparations. Following 1-hr incubations with human microsomes, [14C]THA (0.4 microM) was extensively metabolized to 1-hydroxyTHA with trace amounts of 2-, 4-, and 7-hydroxyTHA also produced. Poor recovery of radioactivity in the postreaction incubates suggested association of THA-derived radioactivity with precipitated microsomal protein. After exhaustive extraction, 0.034, 0.145, 0.126, and 0.012 nmol eq bound/mg protein/60 min of THA-derived radioactivity was bound to human liver preparations H109, H111, H116, and H118, respectively. Preparations H109 and H118 were lower in P4501A2 content and catalytic activity as compared with preparations H111 and H116. Incubations of equimolar [14C]1-hydroxyTHA with human liver microsomes also resulted in binding to protein, although to a lesser extent than observed with THA. [14C]THA (0.4 microM) was incubated for 1 hr with rat liver microsomes (1 microM P-450) prepared from noninduced (N), phenobarbital (PB), isoniazid (I), and 3-methylcholanthrene (3-MC)-pretreated animals. In all incubations, 1-hydroxyTHA was the major biotransformation product detected. After exhaustive extraction, 0.048, 0.054, 0.049, and 0.153 nmol eq/mg protein/60 min of THA-derived radioactivity was bound to microsomal protein from N, PB, I, and 3-MC pretreated rats. Increased binding with 3-MC induced rat liver preparations suggests the involvement of the P-450 1A subfamily in THA bioactivation. Glutathione (5 mM) coincubation inhibited the irreversible binding of THA-derived radioactivity in both human and 3-MC-induced rat liver preparations, whereas human epoxide hydrase (100 micrograms/incubate) had a relative minor effect. A mechanism is proposed involving a putative quinone methide(s) intermediate in the bioactivation and irreversible binding of THA. A species difference in THA-derived irreversible binding exists between human and noninduced rat liver microsomes, suggesting that the rat is a poor model for studying the underlying mechanism(s) of THA-induced elevations in liver marker enzymes found in clinical investigations.
使用人和大鼠肝微粒体制剂研究了他克林(1,2,3,4 - 四氢 - 9 - 吖啶胺盐酸盐一水合物,即THA)的代谢命运。在与人微粒体孵育1小时后,[¹⁴C]THA(0.4微摩尔)被广泛代谢为1 - 羟基THA,同时也产生了痕量的2 -、4 - 和7 - 羟基THA。反应后孵育物中放射性回收率较低,表明THA衍生的放射性与沉淀的微粒体蛋白有关。经过彻底提取后,分别有0.034、0.145、0.126和0.012纳摩尔当量结合/毫克蛋白/60分钟的THA衍生放射性与人类肝脏制剂H109、H111、H116和H118结合。与制剂H111和H116相比,制剂H109和H118的P4501A2含量和催化活性较低。等摩尔的[¹⁴C]1 - 羟基THA与人肝脏微粒体孵育也导致与蛋白结合,尽管程度比THA观察到的要小。[¹⁴C]THA(0.4微摩尔)与从未诱导(N)、苯巴比妥(PB)、异烟肼(I)和3 - 甲基胆蒽(3 - MC)预处理动物制备的大鼠肝微粒体(1微摩尔P - 450)孵育1小时。在所有孵育中,1 - 羟基THA是检测到的主要生物转化产物。经过彻底提取后,分别有0.048、0.054、0.049和0.153纳摩尔当量/毫克蛋白/60分钟的THA衍生放射性与N、PB、I和3 - MC预处理大鼠的微粒体蛋白结合。3 - MC诱导的大鼠中结合增加表明P - 450 1A亚家族参与了THA的生物活化。谷胱甘肽(5毫摩尔)共同孵育抑制了THA衍生放射性在人和3 - MC诱导的大鼠肝脏制剂中的不可逆结合,而人环氧水解酶(100微克/孵育)的影响相对较小。提出了一种机制,涉及THA生物活化和不可逆结合中的假定醌甲基化物中间体。人和未诱导的大鼠肝脏微粒体之间存在THA衍生的不可逆结合的种属差异,这表明大鼠不是研究临床研究中发现的THA诱导肝脏标志物酶升高的潜在机制的良好模型。